PHARMACHON 2025 • SATURDAY, JULY 12 • SAN FRANCISCO, CA
SOURCE: Investors.AscendisPharma.com (June 2, 2025) – Once-weekly TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo – Multiple benefits beyond linear growth were observed compared…
SOURCE: Investors.AscendisPharma.com COPENHAGEN, Denmark, May 13, 2025 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH Trial…
SOURCE: Investors.AscendisPharma.com — Data demonstrated multiple clinical benefits beyond linear growth — NDA supported by data from three randomized, double-blind, placebo-controlled clinical trials in children with achondroplasia, with up to three years…
– TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001) – For children aged 5-11 years TransCon CNP demonstrated…
SOURCE – Ascendis Pharma A/S • Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal…
SOURCE: Ascendis Pharma, GlobeNewswire TransCon CNP is the first investigational product to demonstrate improvements in health-related quality of life and disease impacts in children with achondroplasia COPENHAGEN, Denmark, Dec. 20,…
